Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Episurf Medical AB will exhibit at the London Knee Meeting held in London, UK, on October 3

Episurf Medical (NASDAQ: EPIS B) will exhibit at the London Knee Meeting (recognized as one of the most important meetings in the orthopaedic calendar) held in London, UK (Queen Elizabeth II Conference Centre), on Tuesday October 3. For full program, see http://www.londonkneemeeting.co.uk/. For an overview of the industry conferences attended by Episurf Medical, see link. (www.episurf.com/healthcare-professionals/conferences). For more  information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical

Eniro has received underwriting commitments for the cash issue and extends the acceptance period for the exchange offerings one last time

Eniro has received underwriting commitments for the cash issue amounting to SEK 275 million and extends the acceptance period for the exchange offerings one last time This press release may not be announced, published or distributed, in whole or in part, directly or indirectly, in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, South Africa or any other country where such publication or distribution would violate applicable laws or rules or would require additional documents to be prepared or registered or require any other actions to be taken, in addition

Episurf Medical AB will exhibit at The Individualized TKA, held in Antwerp, Belgium, on September 22

Episurf Medical (NASDAQ: EPIS B) will exhibit at The Individualized TKA (a meeting organized by the Belgian and the Dutch Knee Society) held in Antwerp, Belgium (Elzenveld), on September 22. For full program see http://www.bvot.be/images/programma-uitnodiging.pdf. For an overview of the industry conferences attended by Episurf Medical, see link. (www.episurf.com/healthcare-professionals/conferences). For more  information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is

Nuevolution to present at three investor conferences in September 2017

Stockholm, 11 September 2017 -- Nuevolution AB (publ) (NUE.ST), a leading small-molecule drug-discovery biotech company, today announced that it will be presenting at three investor conferences in the US, Sweden and Denmark in September. First, the company will present at the 19th Annual Rodman & Renshaw Global Investment Conference. The conference will take place on 11-12 September 2017 at the Lotte New York Palace Hotel in New York City. Henrik D. Simonsen, CFO of Nuevolution AB (publ), will provide an overview of the Company’s business during the live presentation on 12 September

Net Gaming redeems existing bond loan

Net Gaming Europe AB (publ) has decided to redeem all outstanding senior secured bonds with ISIN SE000834221 (the "Bonds").Net Gaming Europe AB (publ) has decided to redeem all outstanding Bonds. The redemption will take place on 5 October 2017 with the applicable record date on 28 September 2017. The Bonds will, in connection with the redemption, be delisted from the corporate bond list of Nasdaq First North 26 September 2017. The redemption amount will be established on the redemption date. For further information please contact:Marcus Teilman, President and CEO+356 9936 7352

BillerudKorsnäs production unit in Karlsborg expected to be back to full production during next week

During the night between September 5th and 6th, there was a fire in one of the buildings at BillerudKorsnäs’ production unit in Karlsborg and the production has been stopped since then. After analysing the impact of the fire, BillerudKorsnäs now expects Karlsborg to be back to full production during the week starting with Monday September 18th."The most important thing is that no person has been injured in the fire. We have now assessed the impact of the fire and the work with making the unit ready for start of production is ongoing at high intensity. We expect full production to be reached

New clinical study shows that Probi’s probiotics support the immune system and may delay the onset of gluten intolerance in children

A randomized, double-blind, placebo-controlled intervention trial has evaluated the effect of probiotics from Probi in children genetically predisposed for gluten intolerance (Celiac Disease). The results show that the probiotics have a suppressing effect on celiac autoimmunity and may delay the onset of the disease. Celiac disease affects up to 3% of the population and currently the introduction of a lifelong gluten-free diet is the only available treatment. Consistent study results. The randomized, double-blind, placebo controlled intervention study was performed by Dr. Daniel Agardh (

AppSpotr signs MoU with a Chinese company for restaurant apps

AppSpotr has, via the partly owned subsidiary AppSpotr Asia, signed a Memorandum of Understanding (MoU) with the Chinese company Mishu Technology (MST) to deliver apps to restaurants. The apps will be used for app based marketing, table reservations, ordering of takeout and mobile payments.As a first step, AppSpotr and MST will launch a joint pilot project to build and test the solution in up to 1 000 restaurants. After successful completion of pilot project, then AppSpotr will deliver apps to more restaurants.   The exact costs associated with the development and selling of the app is

Changes in Executive Management in Lundbeck

· Kåre Schultz has resigned from his position as President and CEO to join Teva Pharmaceutical Industries Ltd. as President and CEO · Coincidentally, Staffan Schüberg has also resigned from his position as Chief Commercial Officer to join a privately held company as CEO · The process of finding a replacement for Kåre Schultz and Staffan Schüberg will commence immediately and both will remain in their respective positions until further notice · The Board sees no reason for changes in the strategic direction of the company Valby, Denmark, 11 September 2017 - H. Lundbeck A/S (

IMFINZI superior PFS in Stage III lung cancer

11 September 2017 07:00 BST ASTRAZENECA PRESENTS SUPERIOR PROGRESSION-FREE SURVIVAL FOR IMFINZI IN THE PACIFIC TRIAL OF PATIENTS WITH LOCALLY-ADVANCED UNRESECTABLE LUNG CANCER AT ESMO 2017 CONGRESS Imfinzi improves progression-free survival (PFS) by more than 11 months compared to standard of care and is the first medicine to show superior PFS in this setting Data presented at the ESMO 2017 Congress follows FDA's recent Breakthrough Therapy Designation for Imfinzi in locally advanced, unresectable lung cancer The PACIFIC trial continues to evaluate the other primary endpoint,

Bonava acquires land and creates new homes in Bergen, Norway

Bonava has concluded an agreement for the acquisition of land from Tine SA at a price of approximately SEK 265 million. The property is situated in the Minde neighbourhood, with good transport links todgen city centre. Bonava will construct a total of approximately 300 housing units.- The acquisition is in line with our strategy to increase our market share in Bergen. Minde is an attractive area where we can play a part in continuing to develop happy neighbourhoods where people have the highest quality of life, says Joachim Hallengren, President and CEO of Bonava. The property is located

Mr Green launches predictive Green Gaming tool

Mr Green  announced the launch today of its predictive Green Gaming tool. This unique tool gives players the ability to gain insight into their own risk behavior. At the same time, the tool’s functionality means Mr Green can better detect when healthy playing has moved into the risk zone. "It should feel safe to play at Mr Green, and Green Gaming has been a part of our business strategy since the foundation in 2007,” says Per Norman, CEO of Mr Green & Co. "We have high ambitions, and want to be the brand you associate with Green Gaming.” The new tool analyzes the

Tagrisso potential standard of care in lung cancer

11 September 2017 07:00 BST ASTRAZENECA'S TAGRISSO SHOWS POTENTIAL AS A NEW STANDARD OF CARE IN 1ST-LINE EGFR-MUTATED LUNG CANCER AT ESMO 2017 CONGRESS Phase III FLAURA trial results show Tagrisso reduced the risk of progression or death by more than half, with consistent benefit across all subgroups, including patients with and without brain metastases Unprecedented median progression-free survival (PFS) of 18.9 months compared with 10.2 months for the current standard of care Clinically-meaningful preliminary overall survival benefit AstraZeneca has presented the full

Directorate Changes

11 September 2017      Genel Energy plc       Directorate Changes  Genel Energy plc ('Genel' or 'the Company') announces that Tim Bushell and Martin Gudgeon have been appointed as independent Non-Executive Directors of the Company with immediate effect.  Mr Bushell is a qualified geologist with over 35 years' experience working in the oil and gas sector. He is currently on the Boards of Petro Matad, Rockhopper Exploration, and Point Resources. Previously, he spent a decade as CEO of Falkland Oil & Gas, was a co-founder of Core Energy, and was Managing Director of Paladin

Medivir announces Janssen to discontinue development of JNJ-4178 for hepatitis C

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Research & Development has decided to discontinue the development of the investigational hepatitis C treatment, JNJ-4178, the triple combination of simeprevir, odalasvir and AL-335. Discontinuation of development of JNJ-4178 does not affect the ongoing partnership with Janssen on Olysio® (simeprevir), or the existing licensing agreement with Janssen in which simeprevir is included. Medivir continues to be entitled to royalties on sales of single agent simeprevir globally. The decision to terminate the

Mr Green launches predictive Green Gaming tool

Mr Green  announced the launch today of its predictive Green Gaming tool. This unique tool gives players the ability to gain insight into their own risk behavior. At the same time, the tool’s functionality means Mr Green can better detect when healthy playing has moved into the risk zone."Gaming should be fun, entertaining and safe. Green Gaming is all about staying in control, not crossing the line between enjoyment and risky behaviour.” says Jesper Kärrbrink, CEO of Mr Green Ltd.”  The new tool analyzes the actual playing behavior of a customer and combines it

DDM strengthens organisation to accelerate expansion: Andreas Tuczka becomes new CEO and Gustav Hultgren focuses on the Greek market

DDM Holding AG (First North: DDM) announces that it is expanding its management team to support its continued rapid expansion. The Board of Directors has therefore appointed Andreas Tuczka as the new CEO. The previous CEO, Gustav Hultgren, will focus on the recent significant investment in Greece and future opportunities for rapid expansion in the country.DDM has grown at a fast pace over the last few years. The expansion accelerated during the summer when DDM completed a milestone transaction in Greece with a nominal value of around EUR 1.3 billion. This more than doubled the company’s

Cleantech Invest opens Stockholm Office

Cleantech Invest has opened an office in Stockholm. The purpose of the office, headed by Cleantech Invest partner Timo Linnainmaa, is to support the portfolio companies’ funding rounds and upcoming IPO’s in Sweden, as well as raise awareness of Cleantech Invest as a stock listed opportunity to invest into high growth companies with a positive environmental impact, among private and institutional investors. The purpose of the office, headed up by Timo Linnainmaa, is to support our portfolio companies’ funding rounds and upcoming IPO’s in Sweden, as well as to raise awareness among private

Tethys Oil AB: Tethys Oil to repurchase shares

The Annual General Meeting ("AGM") on 17 May 2017 resolved to authorize the Board of Directors to decide on repurchase of own shares. The Board of Directors has, based on the authorization, decided to initiate the repurchasing program. The main reason for the repurchasing program is to give the company flexibility regarding its equity and thereby optimize the capital structure of the company. Repurchased shares may also be used as payment for, or financing of, acquisitions of companies or businesses or in connection with handling of incentive programs. The repurchase of shares may only

Targovax ASA: Three posters presented at ESMO conference

Oslo, Norway, 11 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that three posters were presented during the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, from September 8-12. Oystein Soug, Chief Executive Officer of Targovax, said, "The ESMO annual conference is a place where clinicians and researchers from all over the world gather to share important information with the goal of finding effective cancer treatments. We are

TF Bank launches deposits in Germany

TF Bank announces that it has successfully launched a EUR deposit account in Germany. By adding German deposits to the company's already established deposit products in Sweden, Finland and Norway, TF Bank is taking the next step towards an even broader diversification of its financing."It is great that we can now offer savings accounts with good rates to private individuals in Germany and at the same time expand our geographical presence. This means that we further strengthen our already diversified financing and that the risks associated with a single country or single currency are reduced"

Bricknode launches Bricknode Fund Manager for fund administration

Bricknode (www.bricknode.com) has launched a new vertical based on the platform Bricknode Financial Systems called Bricknode Fund Manager (www.bricknodefundmanager.com) as a cloud based tool for fund companies to manage their funds, holdings, and investors.Bricknode  has expanded its portfolio of services with Bricknode Fund Manager  which is a cloud based tool for fund companies to manage their funds, holdings, and investors. Fund companies have been struggling with efficiently managing their operations which more often than

There are no items matching the current filter
There are no more items matching the current filter
Back to top